Lisa Alderson, Adela interim CEO
September 25, 2023 09:00 AM EDTUpdated September 30, 12:53 AM
Financing

Lab­corp backs Adela’s $48M Se­ries A1 to ad­vance methy­la­tion-based head and neck can­cer test

Ayisha Sharma

News Reporter

Adela has raised $48 mil­lion in a Se­ries A1 round backed by new in­vestor and di­ag­nos­tic gi­ant Lab­corp to fund a test for mon­i­tor­ing min­i­mal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times